While 2015 was a great year for M&A in the US biotech sector, with deals made by an estimated more than 23% of the companies listed on the NASDAQ Biotechnology Index, that intensity was brought forward into 2016. More that 300 biopharmaceutical agreements totaling US$235 billion were recorded in the first three quarters of the year. Much of the activity is being driven by the massive drop in earnings amid expiring patents of best-selling drugs and a decline in R&D productivity and investment. During the year, based on Mergent analysis, high profile biotech M&A are likely to persist, especially with companies dealing with interesting pipeline candidates or coming out with new therapies. The unconventional biopharma partnerships across the sector should lead most of the activity in 2016. #MergentInc #industryreports #biotechnology
Full material is published in the Mergent Industry Reports
Industry Reports Blog
Highlighting some of the latest industry analysis from our research desk
The Industry Reports are sold as a subscription throughout the United States, Canada, Japan, Australia and Europe. To request a full sample report please complete the the form here.
Blog Post Categories
Get updates on the latest industry news and trends via an RSS feed to your website